The 2025 moves of the big 5 ASC operators

Advertisement

The nation’s five largest ASC companies — United Surgical Partners International, AmSurg, Surgery Partners, HCA Surgery Ventures and SCA Health — have made major moves in 2025, from billion-dollar revenue gains and guidance raises to acquisitions and consolidation. 

Together, their strategies highlight the continued shift toward higher-acuity outpatient care and the growing scale of the ASC market.

USPI (Dallas)

  • USPI added eight  ASCs in the second quarter of 2025 and raised 2025 guidance after a strong second quarter; Tenet now projects USPI adjusted earnings before interest, taxes, debt and amortization of $1.99 billion to $2.05 billion.
  • First-quarter 2025 revenue hit $1.2 billion, up from $995 million year over year, as USPI continued shifting toward higher-acuity cases.
  • USPI is sharpening its focus on orthopedic-driven centers and moving away from lower-acuity, high-volume procedures. 

AmSurg (Nashville, Tenn.)

  • Ascension entered a definitive agreement to acquire AmSurg, vaulting the health system into a top-tier ASC competitor. 
  • Earlier in 2025, AmSurg continued tuck-in acquisitions, including a majority stake in Texarkana (Texas) Surgery Center, as part of a broader growth push. 

Surgery Partners (Nashville)

  • Q2 2025 revenue reached $826.6 million (up 8.4% year over year); same-facility revenue rose 5.1% and cases 3.4%; adjusted EBITDA climbed 9% to $129 million; fiscal 2025 guidance was reaffirmed. 
  • Surgery Partners also rejected a buyout proposal from Bain Capital, signaling confidence in its independent growth strategy.

HCA Surgery Ventures (Dallas)

  • Freestanding ASC count rose to 124 in Q2 2025; outpatient services accounted for 38.4% of total patient revenue as HCA’s ambulatory mix continued to grow. 
  • Same-facility outpatient surgeries dipped 0.6% (inpatient  fell 0.3%) in Q2, while HCA raised full-year 2025 revenue outlook to $74 billion and $76 billion.

SCA Health (Deerfield, Ill.)

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement